Literature DB >> 28628454

Disseminated Mycobacterium genavense Infection in Patient with Adult-Onset Immunodeficiency.

Takanori Asakura, Ho Namkoong, Takuro Sakagami, Naoki Hasegawa, Kiyofumi Ohkusu, Akira Nakamura.   

Abstract

We report a case of disseminated Mycobacterium genavense infection resulting from neutralizing anti-interferon-γ autoantibodies in the patient. We identified M. genavense targeting the hsp65 gene in an aspiration specimen of the lymph node. Adult-onset immunodeficiency caused by neutralizing anti-interferon-γ autoantibodies, in addition to HIV infection, can lead to disseminated nontuberculous mycobacterial infection.

Entities:  

Keywords:  HIV; Japan; Mycobacterium genavense; Tuberculosis and other mycobacteria; adult-onset immunodeficiency; bacteria; nontuberculous mycobacteria

Mesh:

Substances:

Year:  2017        PMID: 28628454      PMCID: PMC5512497          DOI: 10.3201/eid2307.161677

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Mycobacterium genavense is a ubiquitous nontuberculous mycobacteria (NTM), first described as a human infection in the 1990s as a primary cause of fatal disseminated infection in HIV-infected patients with low CD4 counts (). M. genavense also is recognized as an opportunistic pathogen in patients without HIV who have severe immunodeficiency, such as that after solid-organ or hematopoietic stem cell transplantation or immunosuppressive therapy (,). The diagnosis of M. genavense infection is clinically challenging because of the difficulties in routinely culturing the organism and the absence of specific symptoms, even in fatal infections. Therefore, diagnosing M. genavense infection in patients without known evidence of immunodeficiency is particularly difficult. We report a previously healthy 66-year-old man with multiple lymphadenopathies in whom disseminated M. genavense infection resulting from the presence of neutralizing anti–interferon-γ (anti–IFN-γ) autoantibodies was diagnosed. In November 2015, the patient sought care at Asahi General Hospital (Chiba, Japan) for a 2-week history of right-side neck swelling and abdominal pain. His vital signs were within reference ranges. Except for right cervical lymphadenopathy, findings on physical examination were unremarkable. HIV antibodies were undetectable, and CD4/CD8 lymphocyte counts were within reference ranges. No mediastinal or lung involvement was detected on chest computed tomography (CT) scan. Gallium-67 single-photon emission CT/CT revealed high-intensity accumulation of the right cervical and ileocolic lymph nodes (Technical Appendix Figure). Acid-fast bacilli (AFB) staining of the lymph-node aspiration specimen yielded positive results; however, findings on solid media culture and PCR for detecting M. tuberculosis, M. avium, and M. intracellulare were negative. After a 6-week outpatient follow-up, the patient returned with newly developed right axillary lymphadenopathy. An aspiration specimen of the lymph node showed positive AFB staining and was submitted for molecular biologic analysis. M. genavense was identified on amplification and sequencing analysis targeting the hsp65 gene (). We strongly suspected neutralizing anti–IFN-γ autoantibodies as the cause because the whole blood IFN-γ level with mitogen stimulation was low, as determined using an IFN-γ–releasing assay (QuantiFERON TB 3G; Cellestis, Carnagie, VIC, Australia). A high serum-neutralizing anti–IFN-γ autoantibody titer and inhibited STAT1 (signal transducer and activator of transcription 1) phosphorylation through IFN-γ stimulation in the leukocytes were confirmed, leading to a diagnosis of disseminated M. genavense infection. Clarithromycin, ethambutol, rifampin, and amikacin were administered. Lymphadenopathy improved after 6 weeks, and amikacin was discontinued. No relapse occurred during 16 months of treatment. Recent studies have described disseminated NTM infection in patients in Asia with adult-onset immunodeficiency resulting from neutralizing anti–IFN-γ autoantibodies (–). Disseminated infection mainly involves the lymph nodes, followed by the osteoarticular system, bone, lungs, and skin (,). The pathogen comprises rapidly and slowly growing mycobacteria; M. avium complex and M. abscessus are the most frequently detected. Although the long-term outcome is unclear, most patients need long-term antimicrobial therapy, and some relapses occur after treatment discontinuation (,). Adjuvant rituximab therapy has been used for refractory disease (). Although disseminated M. genavense infections formerly only were known to occur in HIV-infected patients, the epidemiologic shift to infections in patients without HIV reflects the introduction of combination antiretroviral therapy and increasing use of immunosuppressive agents (). In 2 previous series comprising 14 HIV-negative patients with M. genavense infection, most patients had known evidence of immunodeficiency; of the 12 patients treated with immunosuppressive agents, 5 had sarcoidosis, 5 were solid-organ transplantation recipients, 1 had non-Hodgkin lymphoma, and 1 had rheumatoid arthritis. Only 2 patients were identified with adult-onset innate immunodeficiency (,); 1 patient had innate interleukin-12 receptor deficiency and 1 had idiopathic CD4 lymphocytopenia. Needle aspirates and tissue biopsy provide higher NTM diagnostic yields than does swab sampling but are insufficiently sensitive. Therefore, less frequently encountered mycobacterial species are identified by gene sequencing, reverse hybridization, and high-performance liquid chromatography (). Moreover, the identification of M. genavense infection using standard mycobacterial culture methods is difficult. Acidified solid media testing with blood and charcoal is probably the most suitable method (); however, accurate diagnosis requires additional molecular biologic analysis, such as amplification and sequencing of the 16S ribosomal RNA, hsp65, or rpoB genes. In this case, we identified M. genavense using a direct molecular biologic method for aspiration specimens from the lymph node. Little is known about death among HIV-negative patients with M. genavense infection, although some patients reportedly have died (,). Although their conditions eventually improve, despite a lack of early identification of M. genavense, delayed diagnosis might influence death. Direct molecular biologic methods could better identify M. genavense infection and improve prognosis. We report a case of disseminated M. genavense infection resulting from neutralizing anti–IFN-γ autoantibodies in the patient. M. genavense infection should be considered in the differential diagnosis of mycobacteria detected with AFB staining but not with culture, even in patients without known evidence of immunodeficiency. Adult-onset immunodeficiency acquired by neutralizing anti–IFN-γ autoantibodies, in addition to HIV infection, can lead to disseminated NTM infection.

Technical Appendix

Gallium-67 single-photon emission computed tomography/computed tomography showing high-intensity accumulation of Mycobacterium genavense in the right cervical (A) and ileocolic (B) lymph nodes of a 66-year-old previously healthy man.
  10 in total

1.  Routine rapid Mycobacterium species assignment based on species-specific allelic variation in the 65-kilodalton heat shock protein gene (hsp65).

Authors:  S Pai; N Esen; X Pan; J M Musser
Journal:  Arch Pathol Lab Med       Date:  1997-08       Impact factor: 5.534

2.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors:  Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

3.  Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases.

Authors:  W Hoefsloot; J van Ingen; E J G Peters; C Magis-Escurra; P N R Dekhuijzen; M J Boeree; D van Soolingen
Journal:  Clin Microbiol Infect       Date:  2012-03-22       Impact factor: 8.067

4.  Blood and charcoal added to acidified agar media promote the growth of Mycobacterium genavense.

Authors:  L Realini; K De Ridder; B Hirschel; F Portaels
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

5.  Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007.

Authors:  Pierre Charles; Olivier Lortholary; Agnès Dechartres; Fahranoosh Doustdar; Jean Paul Viard; Marc Lecuit; Maria Cristina Gutierrez
Journal:  Medicine (Baltimore)       Date:  2011-07       Impact factor: 1.889

6.  Adult-onset immunodeficiency in Thailand and Taiwan.

Authors:  Sarah K Browne; Peter D Burbelo; Ploenchan Chetchotisakd; Yupin Suputtamongkol; Sasisopin Kiertiburanakul; Pamela A Shaw; Jennifer L Kirk; Kamonwan Jutivorakool; Rifat Zaman; Li Ding; Amy P Hsu; Smita Y Patel; Kenneth N Olivier; Viraphong Lulitanond; Piroon Mootsikapun; Siriluck Anunnatsiri; Nasikarn Angkasekwinai; Boonmee Sathapatayavongs; Po-Ren Hsueh; Chi-Chang Shieh; Margaret R Brown; Wanna Thongnoppakhun; Reginald Claypool; Elizabeth P Sampaio; Charin Thepthai; Duangdao Waywa; Camilla Dacombe; Yona Reizes; Adrian M Zelazny; Paul Saleeb; Lindsey B Rosen; Allen Mo; Michael Iadarola; Steven M Holland
Journal:  N Engl J Med       Date:  2012-08-23       Impact factor: 91.245

7.  Disseminated Mycobacterium genavense infection: clinical and microbiological features and response to therapy.

Authors:  M T Bessesen; J Shlay; B Stone-Venohr; D L Cohn; R R Reves
Journal:  AIDS       Date:  1993-10       Impact factor: 4.177

Review 8.  Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons.

Authors:  Claudio Piersimoni; Claudio Scarparo
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

Review 9.  Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection.

Authors:  Florent Valour; Thomas Perpoint; Agathe Sénéchal; Xiao-Fei Kong; Jacinta Bustamante; Tristan Ferry; Christian Chidiac; Florence Ader
Journal:  Emerg Infect Dis       Date:  2016-06       Impact factor: 6.883

10.  Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections.

Authors:  Chih-Yu Chi; Chia-Hao Lin; Mao-Wang Ho; Jing-Ya Ding; Wen-Chi Huang; Han-Po Shih; Chun-Fu Yeh; Chang-Phone Fung; Hsin-Yun Sun; Ching-Tai Huang; Ting-Shu Wu; Chih-Yen Chang; Yuag-Meng Liu; Jia-Yih Feng; Wei-Kai Wu; Lih-Shinn Wang; Chung-Hao Tsai; Cheng-Mao Ho; Huang-Shen Lin; Hung-Jen Chen; Po-Chang Lin; Wei-Chin Liao; Wei-Ting Chen; Chia-Chi Lo; Shang-Yu Wang; Chen-Yen Kuo; Chen-Hsiang Lee; Cheng-Lung Ku
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  10 in total
  4 in total

1.  Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States.

Authors:  Gloria H Hong; Ana M Ortega-Villa; Sally Hunsberger; Ploenchan Chetchotisakd; Siriluck Anunnatsiri; Piroon Mootsikapun; Lindsey B Rosen; Christa S Zerbe; Steven M Holland
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

2.  First report of hepatobiliary Mycobacterium avium infection developing obstructive jaundice in a patient with neutralizing anti-interferon-gamma autoantibodies.

Authors:  H Namkoong; T Asakura; M Ishii; S Yoda; K Masaki; T Sakagami; E Iwasaki; Y Yamagishi; T Kanai; T Betsuyaku; N Hasegawa
Journal:  New Microbes New Infect       Date:  2018-10-19

Review 3.  Functional Analysis of Anti-cytokine Autoantibodies Using Flow Cytometry.

Authors:  Patricia A Merkel; Terri Lebo; Vijaya Knight
Journal:  Front Immunol       Date:  2019-07-12       Impact factor: 7.561

Review 4.  Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity.

Authors:  Georgios Sogkas; Faranaz Atschekzei; Ignatius Ryan Adriawan; Natalia Dubrowinskaja; Torsten Witte; Reinhold Ernst Schmidt
Journal:  Cell Mol Immunol       Date:  2021-04-01       Impact factor: 11.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.